# A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps

> **NCT04783389** · PHASE2 · TERMINATED · sponsor: **Connect Biopharm LLC** · enrollment: 40 (actual)

## Conditions studied

- Chronic Rhinosinusitis With Nasal Polyps

## Interventions

- **DRUG:** CBP-201
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04783389
- **Lead sponsor:** Connect Biopharm LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-16
- **Primary completion:** 2022-04-15
- **Final completion:** 2022-06-10
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Trial was discontinued in 2022 due to COVID-19 pandemic and Ukraine/Russia conflict related enrollment challenges. Discontinuation was not related to safety.
- **Last updated:** 2023-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04783389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04783389, "A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04783389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*